Effects of Pulmonary Diseases and Their Treatment on Cardiac Function
Launched by AYHAM DAHER · Sep 10, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how lung diseases, like COPD (chronic obstructive pulmonary disease), bronchial asthma, and idiopathic pulmonary fibrosis, affect heart function. Researchers want to understand how treatments for these lung diseases may also influence the heart. They will use advanced imaging techniques called cardiac MRI to look at heart function and structure in patients with these conditions, both when they are first diagnosed and after starting treatment. The goal is to identify any heart problems early on and see how treatment helps over time.
To be eligible for the trial, participants must be over 18 years old and have a chronic lung disease that requires treatment. It's important that they can give informed consent, meaning they understand what the study involves. Participants will undergo cardiac MRI and echocardiography (another type of heart imaging) to assess their heart health. They can expect to be closely monitored for 3 to 6 months after they start their treatment to see how their heart function changes. This study is crucial for improving our understanding of the connection between lung and heart health, which can help doctors provide better care for patients with these diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with chronic lung disease requiring treatment (COPD, asthma, or pulmonary fibrosis).
- • Age \> 18 years
- • Informed consent to participate in the study will sign
- Exclusion Criteria:
- • Individuals who are not fully capable of giving consent and understanding the nature, significance and scope of the study.
- • Patients with contraindications to MRI examination (eg, pacemaker, severe claustrophobia) or to contrast medium use (severe renal insufficiency or glomerular filtration rate \<30 ml/min, known gadolinium contrast medium allergy)
- • Patients with atrial fibrillation or other significant cardiac arrhythmias that interfere with cardiac MRI
- • Pregnancy and lactation
About Ayham Daher
Ayham Daher is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and rigorous scientific methodology, Ayham Daher leads and collaborates on clinical studies across various therapeutic areas. The organization prioritizes ethical standards, patient safety, and regulatory compliance, ensuring that all trials are conducted with the highest level of integrity. Through strategic partnerships and a robust infrastructure, Ayham Daher aims to accelerate the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aachen, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials